류마티스 관절염 치료제 시장 규모, 점유율, 동향 분석 보고서 : 분자별, 판매 채널별, 지역별, 부문별 예측(2025-2033년)

Rheumatoid Arthritis Therapeutics Market Size, Share & Trends Analysis Report By Molecule (Pharmaceuticals, Biopharmaceuticals), By Sales Channel (Prescription, Over-the-Counter), By Region, And Segment Forecasts, 2025 - 2033

US $ 5,950 ￦ 8,539,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,974,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,845,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

류마티스 관절염 치료제 시장 요약

세계 류마티스 관절염 치료제 시장 규모는 2024년에 257억 6,000만 달러로 추정되며, 2033년에는 414억 2,000만 달러에 달할 것으로 예상되며, 2025년부터 2033년까지 5.56%의 CAGR로 성장할 것으로 예상됩니다.

류마티스 관절염(RA)에 대한 혁신적인 치료제의 도입이 시장 성장에 중요한 역할을 하고 있습니다.

Amgen Inc., Pfizer Inc., Genentech, Inc., Novartis 등 주요 기업들이 Cyltezo, Hyrimoz, Amgevita, Erelzi, Absola, Rituximab 등 새로운 바이오시밀러를 출시하면서 RA 치료의 전망을 RA 치료의 전망을 크게 바꿔놓았습니다. 예를 들어, 2024년 5월 베링거인겔하임은 미국 식품의약국(FDA)이 리툭시맙을 승인했다고 발표했습니다. 또한, 베링거인겔하임은 2024년 5월 미국 식품의약국(FDA)이 류마티스 관절염, 크론병, 궤양성 대장염, 건선, 건선성 관절염, 농포성 한선염, 강직성 척추염, 중등도에서 중증의 심상성 건선, 비감염성 포도막염을 포함한 여러 만성 염증성 질환의 치료제로 휴미라의 휴미라의 바이오시밀러인 실테조(아달리무맙-adbm)의 구연산염을 함유하지 않은 고농도 제제를 승인받았다고 밝혔습니다.

이와 유사한 진전으로, 2023년 1월 노바티스 AG는 샌드 구연산염을 함유하지 않은 하이리모즈(아달리무맙) 고농도 제제(HCF)에 대해 유럽의약품청 산하 약물사용자문위원회(CHMP)로부터 판매 승인을 받았습니다. 이번 승인은 RA, 포도막염, 궤양성 대장염, 심상성 건선을 포함한 기준약의 모든 적응증으로 확대됩니다. 이러한 차세대 바이오의약품과 바이오시밀러는 관절통과 염증을 유발하는 특정 면역계 분자와 수용체에 작용하도록 설계되어 치료 효과를 향상시킬 수 있습니다. 이러한 표적화된 효율적인 치료에 대한 수요 증가는 RA에 대한 생물학적 제제 치료의 진보를 더욱 촉진할 것으로 예상됩니다.

최근 RA의 치료 전략은 질병의 완화를 유도할 수 있는 새로운 분자로 전환되고 있습니다. 이러한 진화는 RA의 근본적인 메커니즘에 대한 이해가 깊어지면서 표적 생물학적 제제 및 합성 질환 조절 항류마티스제제(DMARDs)의 탄생으로 이어졌습니다. 현재도 저분자 DMARDs, 코르티코스테로이드, 진통제, 비스테로이드성 항염증제(NSAIDs) 등이 1차 선택 약물로 사용되고 있지만, 이러한 치료법은 RA를 완치하기보다는 질병의 진행을 늦추거나 염증을 억제하는 것이 주요 목적입니다. 또한 소화관 궤양, 면역 억제, 골다공증, 메스꺼움, 세포 감소, 피로, 피부 발진, 간 손상, 건선, 감염 위험 증가 등의 부작용이 나타날 수 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 류마티스 관절염 치료제 시장 변수, 동향, 범위

• 시장 계통 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 비즈니스 환경 분석
  • 업계 분석 - Porter's Five Forces 분석
  • PESTLE 분석
  • 파이프라인 분석
  • 특허 만료 분석
  • 가격 분석

제4장 류마티스 관절염 치료제 시장 : 분자 비즈니스 분석

• 분자 시장 점유율, 2024년 및 2033년
• 분자 부문 대시보드
• 시장 규모와 예측 및 동향 분석, 분자별, 2021-2033년
• 의약품
• 바이오의약품

제5장 류마티스 관절염 치료제 시장 : 판매 채널 비즈니스 분석

• 판매 채널 시장 점유율, 2024년 및 2033년
• 판매 채널 부문 대시보드
• 시장 규모와 예측 및 동향 분석, 판매 채널별, 2021-2033년
• 처방전
• 시판약(OTC)

제6장 류마티스 관절염 치료제 시장 : 지역별 추정·동향 분석

• 지역별 시장 점유율 분석, 2024년 및 2033년
• 지역 시장 대시보드
• 시장 규모와 예측 동향 분석, 2021-2033년 :
• 북미
  • 국가별, 2021-2033년
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제7장 경쟁 구도

• 참여자 개요
• 기업의 시장 포지션 분석
• 기업 분류
• 전략 매핑
• 기업 개요/상장 기업
  • AbbVie, Inc.
  • Boehringer Ingelheim International GmbH
  • Novartis AG
  • Regeneron Pharmaceuticals Inc.
  • Pfizer, Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • UCB SA
  • Johnson & Johnson Services, Inc.
  • Amgen, Inc.
  • Lilly(Eli Lilly and Company)

KSM

영문 목차

영문목차

Rheumatoid Arthritis Therapeutics Market Summary

The global rheumatoid arthritis therapeutics market size was estimated at USD 25.76 billion in 2024 and is projected to reach USD 41.42 billion by 2033, growing at a CAGR of 5.56% from 2025 to 2033. The introduction of innovative therapeutics for rheumatoid arthritis (RA) is playing a key role in boosting market growth.

The launch of new biosimilars such as Cyltezo, Hyrimoz, Amgevita, Erelzi, Avsola, and Rituximab by leading pharmaceutical companies including Amgen Inc., Pfizer Inc., Genentech, Inc., and Novartis has significantly reshaped the RA treatment landscape. For instance, In May 2024, Boehringer Ingelheim announced that the U.S. Food and Drug Administration had approved a high-concentration, citrate-free formulation of Cyltezo (adalimumab-adbm) the company's interchangeable biosimilar to Humira for treating multiple chronic inflammatory diseases including rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, psoriatic arthritis, hidradenitis suppurativa, ankylosing spondylitis, moderate-to-severe plaque psoriasis, and non-infectious uveitis.

In a similar development, January 2023 saw Novartis AG secure marketing authorization from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for Sandoz's citrate-free, high-concentration formulation (HCF) of Hyrimoz (adalimumab). This approval extends to all indications of the reference medicine, including RA, uveitis, ulcerative colitis, and plaque psoriasis. These next-generation biologics and biosimilars are designed to act on specific immune system molecules or receptors responsible for joint pain and inflammation, resulting in improved treatment outcomes. Rising demand for such targeted and efficient therapies is expected to further drive advancements in biologic treatments for RA.

In recent years, RA treatment strategies have shifted toward newer molecules capable of inducing disease remission. This evolution stems from a deeper understanding of RA's underlying mechanisms, leading to the creation of targeted biologic and synthetic disease-modifying antirheumatic drugs (DMARDs). While first-line treatment still includes small-molecule DMARDs, corticosteroids, analgesics, and nonsteroidal anti-inflammatory drugs (NSAIDs), these options primarily slow disease progression and manage inflammation rather than curing the condition. Moreover, they can cause notable side effects, such as gastrointestinal ulcers, immunosuppression, osteoporosis, nausea, cytopenia, fatigue, skin rashes, liver damage, psoriasis, and an increased risk of infections.

Global Rheumatoid Arthritis Therapeutics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global rheumatoid arthritis therapeutics market report based on molecule, sales channel, and region:

• Molecule Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceuticals
  • NSAIDs
  • Analgesics
  • DMARDs
  • Glucocorticoids
• Biopharmaceuticals
  • Biologics
  • TNF-a antagonists
  • T-cell inhibitors
  • CD20 antigen
  • JAK inhibitors
  • Anti-IL6 biologics
  • Biosimilars
  • CD20 antigen
  • TNF-a antagonists
• Sales Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Prescription
• Over-the-Counter (OTC)
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Molecule
  • 1.2.2. Sales Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Rheumatoid Arthritis Therapeutics Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Rheumatoid Arthritis Therapeutics Market: Molecule Business Analysis

• 4.1. Molecule Market Share, 2024 & 2033
• 4.2. Molecule Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Molecule, 2021 to 2033 (USD Million)
• 4.4. Pharmaceuticals
  • 4.4.1. Pharmaceuticals Market, 2021 - 2033 (USD Million)
  • 4.4.2. NSAIDs
    • 4.4.2.1. NSAIDs Market, 2021 - 2033 (USD Million)
  • 4.4.3. Analgesics
    • 4.4.3.1. Analgesics Market, 2021 - 2033 (USD Million)
  • 4.4.4. DMARDs
    • 4.4.4.1. DMARDs Market, 2021 - 2033 (USD Million)
  • 4.4.5. Glucocorticoids
    • 4.4.5.1. Glucocorticoids Market, 2021 - 2033 (USD Million)
• 4.5. Biopharmaceuticals
  • 4.5.1. Biopharmaceuticals Market, 2021 - 2033 (USD Million)
  • 4.5.2. Biologics
    • 4.5.2.1. Biologics Market, 2021 - 2033 (USD Million)
    • 4.5.2.2. TNF-a antagonists
      • 4.5.2.2.1. TNF-a antagonists Market, 2021 - 2033 (USD Million)
    • 4.5.2.3. T-cell inhibitors
      • 4.5.2.3.1. T-cell inhibitors Market, 2021 - 2033 (USD Million)
    • 4.5.2.4. CD20 antigen
      • 4.5.2.4.1. CD20 antigen Market, 2021 - 2033 (USD Million)
    • 4.5.2.5. JAK inhibitors
      • 4.5.2.5.1. JAK inhibitors Market, 2021 - 2033 (USD Million)
    • 4.5.2.6. Anti-IL6 biologics
      • 4.5.2.6.1. Anti-IL6 biologics Market, 2021 - 2033 (USD Million)
  • 4.5.3. Biosimilars
    • 4.5.3.1. Biosimilars Market, 2021 - 2033 (USD Million)
    • 4.5.3.2. CD20 antigen
      • 4.5.3.2.1. CD20 antigen Market, 2021 - 2033 (USD Million)
    • 4.5.3.3. TNF-a antagonists
      • 4.5.3.3.1. TNF-a antagonists Market, 2021 - 2033 (USD Million)

Chapter 5. Rheumatoid Arthritis Therapeutics Market: Sales Channel Business Analysis

• 5.1. Sales Channel Market Share, 2024 & 2033
• 5.2. Sales Channel Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Sales Channel, 2021 to 2033 (USD Million)
• 5.4. Prescription
  • 5.4.1. Prescription Market, 2021 - 2033 (USD Million)
• 5.5. Over-the-Counter (OTC)
  • 5.5.1. Over-the-Counter (OTC) Market, 2021 - 2033 (USD Million)

Chapter 6. Rheumatoid Arthritis Therapeutics Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2024 & 2033
• 6.2. Regional Market Dashboard
• 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 6.4. North America
  • 6.4.1. North America Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
  • 6.4.2. U.S.
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Target Disease Prevalence
    • 6.4.2.3. Regulatory Framework
    • 6.4.2.4. Reimbursement Framework
    • 6.4.2.5. U.S. Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.3. Canada
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Target Disease Prevalence
    • 6.4.3.3. Regulatory Framework
    • 6.4.3.4. Reimbursement Framework
    • 6.4.3.5. Canada Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.4. Mexico
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Target Disease Prevalence
    • 6.4.4.3. Regulatory Framework
    • 6.4.4.4. Reimbursement Framework
    • 6.4.4.5. Mexico Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Europe
  • 6.5.1. Europe Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.2. UK
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Target Disease Prevalence
    • 6.5.2.3. Regulatory Framework
    • 6.5.2.4. Reimbursement Framework
    • 6.5.2.5. UK Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.3. Germany
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Target Disease Prevalence
    • 6.5.3.3. Regulatory Framework
    • 6.5.3.4. Reimbursement Framework
    • 6.5.3.5. Germany Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.4. France
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Target Disease Prevalence
    • 6.5.4.3. Regulatory Framework
    • 6.5.4.4. Reimbursement Framework
    • 6.5.4.5. France Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.5. Italy
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Target Disease Prevalence
    • 6.5.5.3. Regulatory Framework
    • 6.5.5.4. Reimbursement Framework
    • 6.5.5.5. Italy Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.6. Spain
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Target Disease Prevalence
    • 6.5.6.3. Regulatory Framework
    • 6.5.6.4. Reimbursement Framework
    • 6.5.6.5. Spain Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.7. Denmark
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Target Disease Prevalence
    • 6.5.7.3. Regulatory Framework
    • 6.5.7.4. Reimbursement Framework
    • 6.5.7.5. Denmark Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.8. Sweden
    • 6.5.8.1. Key Country Dynamics
    • 6.5.8.2. Target Disease Prevalence
    • 6.5.8.3. Regulatory Framework
    • 6.5.8.4. Reimbursement Framework
    • 6.5.8.5. Sweden Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.9. Norway
    • 6.5.9.1. Key Country Dynamics
    • 6.5.9.2. Target Disease Prevalence
    • 6.5.9.3. Regulatory Framework
    • 6.5.9.4. Reimbursement Framework
    • 6.5.9.5. Norway Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Asia Pacific Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.2. Japan
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Target Disease Prevalence
    • 6.6.2.3. Regulatory Framework
    • 6.6.2.4. Reimbursement Framework
    • 6.6.2.5. Japan Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.3. China
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Target Disease Prevalence
    • 6.6.3.3. Regulatory Framework
    • 6.6.3.4. Reimbursement Framework
    • 6.6.3.5. China Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.4. India
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Target Disease Prevalence
    • 6.6.4.3. Regulatory Framework
    • 6.6.4.4. Reimbursement Framework
    • 6.6.4.5. India Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.5. Australia
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Target Disease Prevalence
    • 6.6.5.3. Regulatory Framework
    • 6.6.5.4. Reimbursement Framework
    • 6.6.5.5. Australia Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.6. South Korea
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Target Disease Prevalence
    • 6.6.6.3. Regulatory Framework
    • 6.6.6.4. Reimbursement Framework
    • 6.6.6.5. South Korea Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.7. Thailand
    • 6.6.7.1. Key Country Dynamics
    • 6.6.7.2. Target Disease Prevalence
    • 6.6.7.3. Regulatory Framework
    • 6.6.7.4. Reimbursement Framework
    • 6.6.7.5. Thailand Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Latin America
  • 6.7.1. Latin America Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.2. Brazil
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Target Disease Prevalence
    • 6.7.2.3. Regulatory Framework
    • 6.7.2.4. Reimbursement Framework
    • 6.7.2.5. Brazil Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.3. Argentina
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Target Disease Prevalence
    • 6.7.3.3. Regulatory Framework
    • 6.7.3.4. Reimbursement Framework
    • 6.7.3.5. Argentina Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.8. Middle East and Africa
  • 6.8.1. Middle East and Africa Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8.2. South Africa
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Target Disease Prevalence
    • 6.8.2.3. Regulatory Framework
    • 6.8.2.4. Reimbursement Framework
    • 6.8.2.5. South Africa Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Target Disease Prevalence
    • 6.8.3.3. Regulatory Framework
    • 6.8.3.4. Reimbursement Framework
    • 6.8.3.5. Saudi Arabia Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8.4. UAE
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. Target Disease Prevalence
    • 6.8.4.3. Regulatory Framework
    • 6.8.4.4. Reimbursement Framework
    • 6.8.4.5. UAE Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8.5. Kuwait
    • 6.8.5.1. Key Country Dynamics
    • 6.8.5.2. Target Disease Prevalence
    • 6.8.5.3. Regulatory Framework
    • 6.8.5.4. Reimbursement Framework
    • 6.8.5.5. Kuwait Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Participant Overview
• 7.2. Company Market Position Analysis
• 7.3. Company Categorization
• 7.4. Strategy Mapping
• 7.5. Company Profiles/Listing
  • 7.5.1. AbbVie, Inc.
    • 7.5.1.1. Overview
    • 7.5.1.2. Financial Performance
    • 7.5.1.3. Molecule Benchmarking
    • 7.5.1.4. Strategic Initiatives
  • 7.5.2. Boehringer Ingelheim International GmbH
    • 7.5.2.1. Overview
    • 7.5.2.2. Financial Performance
    • 7.5.2.3. Molecule Benchmarking
    • 7.5.2.4. Strategic Initiatives
  • 7.5.3. Novartis AG
    • 7.5.3.1. Overview
    • 7.5.3.2. Financial Performance
    • 7.5.3.3. Molecule Benchmarking
    • 7.5.3.4. Strategic Initiatives
  • 7.5.4. Regeneron Pharmaceuticals Inc.
    • 7.5.4.1. Overview
    • 7.5.4.2. Financial Performance
    • 7.5.4.3. Molecule Benchmarking
    • 7.5.4.4. Strategic Initiatives
  • 7.5.5. Pfizer, Inc.
    • 7.5.5.1. Overview
    • 7.5.5.2. Financial Performance
    • 7.5.5.3. Molecule Benchmarking
    • 7.5.5.4. Strategic Initiatives
  • 7.5.6. Bristol-Myers Squibb Company
    • 7.5.6.1. Overview
    • 7.5.6.2. Financial Performance
    • 7.5.6.3. Molecule Benchmarking
    • 7.5.6.4. Strategic Initiatives
  • 7.5.7. F. Hoffmann-La Roche Ltd.
    • 7.5.7.1. Overview
    • 7.5.7.2. Financial Performance
    • 7.5.7.3. Molecule Benchmarking
    • 7.5.7.4. Strategic Initiatives
  • 7.5.8. UCB S.A.
    • 7.5.8.1. Overview
    • 7.5.8.2. Financial Performance
    • 7.5.8.3. Molecule Benchmarking
    • 7.5.8.4. Strategic Initiatives
  • 7.5.9. Johnson & Johnson Services, Inc.
    • 7.5.9.1. Overview
    • 7.5.9.2. Financial Performance
    • 7.5.9.3. Molecule Benchmarking
    • 7.5.9.4. Strategic Initiatives
  • 7.5.10. Amgen, Inc.
    • 7.5.10.1. Overview
    • 7.5.10.2. Financial Performance
    • 7.5.10.3. Molecule Benchmarking
    • 7.5.10.4. Strategic Initiatives
  • 7.5.11. Lilly (Eli Lilly and Company)
    • 7.5.11.1. Overview
    • 7.5.11.2. Financial Performance
    • 7.5.11.3. Molecule Benchmarking
    • 7.5.11.4. Strategic Initiatives

관련자료